ReviewDrugs2004
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.
Review in Drugs, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 304 citations in OpenAlex.
- Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.Bone marrow transplantation · 2019Pooled it
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- Expert prior elicitation and Bayesian analysis of the Mycotic Ulcer Treatment Trial I.Investigative ophthalmology & visual science · 2013Trial
- Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Antimicrobial agents and chemotherapy · 2010Trial
- Comparison of natamycin and voriconazole for the treatment of fungal keratitis.Archives of ophthalmology (Chicago, Ill. : 1960) · 2010Trial
- Voriconazole and fluconazole increase the exposure to oral diazepam.European journal of clinical pharmacology · 2007Trial
- Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects.British journal of clinical pharmacology · 2007Trial
- Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis.European journal of drug metabolism and pharmacokineticsTrial
- Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance.The Journal of antimicrobial chemotherapy · 2026Article
- Therapeutic Drug Monitoring of Antimicrobial Drugs in Children with Cancer: A New Tool for Personalized Medicine.Paediatric drugs · 2025Review
- Idiopathic aplastic anemia with concurrent complications of colonic perforation and mucormycosis: Case report.Heliyon · 2024Article
- Caspofungin-Loaded Formulations for Treating Ocular Infections Caused byGels (Basel, Switzerland) · 2023Article
- Non-European respiratory review : an official journal of the European Respiratory Society · 2022Article
- Mucormycosis infection in hematopoietic stem cell transplant patients: A serious threat.Annals of medicine and surgery (2012) · 2022Article
- Essential Oils in Respiratory Mycosis: A Review.Molecules (Basel, Switzerland) · 2022Review
- New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis.Gels (Basel, Switzerland) · 2021Article
- Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.PLoS neglected tropical diseases · 2020Review
- New Approaches for Cryptococcosis Treatment.Microorganisms · 2020Review
- Evaluation of a Novel Mitochondrial Pan-Journal of fungi (Basel, Switzerland) · 2019Article
- Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past few years have seen the advent of several new antifungal agents, including those of a new class and a new generation of an existing class. Caspofungin, the first available echinocandin, has greatly expanded the antifungal armamentarium by providing a cell wall-active agent with candidacidal activity as well as demonstrated clinical efficacy in the therapy of aspergillosis refractory to available therapy. In addition, in clinical trials, caspofungin had comparable efficacy to amphotericin B for candidaemia and invasive Candida infections. Caspofungin and two more recently introduced echinocandins, micafungin and anidulafungin, are available as intravenous formulations only and characterised by potent anti-candidal activity, as well as few adverse events and drug interactions. Voriconazole, the first available second-generation triazole, available in both intravenous and oral formulations, has added a new and improved therapeutic option for primary therapy of invasive aspergillosis and salvage therapy for yeasts and other moulds. In a randomised trial, voriconazole demonstrated superior efficacy and a survival benefit compared with amphotericin B followed by other licensed antifungal therapy. This and data from a noncomparative study led to voriconazole becoming a new standard of therapy for invasive aspergillosis. Voriconazole has several important safety issues, including visual adverse events, hepatic enzyme elevation and skin reactions, as well as a number of drug interactions. Posaconazole, only available orally and requiring dose administration four times daily, shows encouraging efficacy in difficult to treat infections due to zygomycetes. Ravuconazole, available in both intravenous and oral formulations, has broad-spectrum in vitro potency and in vivo efficacy against a wide range of fungal pathogens. Clinical studies are underway. Despite the advances offered with each of these drugs, the morbidity and mortality associated with invasive fungal infections remains unacceptable, especially for the most at-risk patients. For individuals with severe immunosuppression as a result of chemotherapy, graft-versus-host disease and its therapy, or transplantation, new drugs and strategies are greatly needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.